Article pour les cliniciens
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
PMID: 41662710
-
Médecine interne (voir sous-spécialités ci-dessous)Relevance - 7/7
Intérêt médiatique - 6/7 -
Médecine familiale (MF)/Médecine générale (MG)Relevance - 6/7
Intérêt médiatique - 6/7 -
Médecine interne générale - Soins primairesRelevance - 6/7
Intérêt médiatique - 6/7 -
- Maladies infectieusesRelevance - 6/7
Intérêt médiatique - 5/7 -
Santé publiqueRelevance - 6/7
Intérêt médiatique - 5/7
Résumé (en anglais)
BACKGROUND: Clinicians and patients need updated information on antiviral treatments for COVID-19.
PURPOSE: To provide a final update on the benefits and harms of COVID-19 antiviral treatments in adult outpatients.
DATA SOURCES: Ovid/MEDLINE, Epistemonikos COVID-19 L·OVE platform, and iSearch COVID-19 portfolio (22 January 2025); Ovid/MEDLINE (24 September 2025).
STUDY SELECTION: Two reviewers screened 20% of abstracts and full texts, then single screening. Randomized controlled trials were included for benefits and harms, and cohort studies were included for harms.
DATA EXTRACTION: One reviewer extracted data and assessed risk of bias and certainty of evidence (CoE); a second reviewer verified.
DATA SYNTHESIS: Seven studies from the Omicron period were included. 125 mg of ensitrelvir may not reduce time to recovery and may result in no difference in serious adverse events (both low CoE) but may increase adverse events (44.2% vs. 24.8%; low CoE). Molnupiravir probably improves recovery (31.8% vs. 22.6%) and reduces time to recovery (9 vs. 15 median days) and persistent symptoms from 3 to 6 months (8.5% vs. 11.0%), with no effect on mortality, hospitalization, serious adverse events, and adverse events (all moderate CoE). Nirmatrelvir-ritonavir may increase recovery (70.7% vs. 53.6%; low CoE) and reduce time to recovery (no data, P = 0.011; low CoE) but probably increases adverse events (1.3% vs. 1.0%; moderate CoE). Simnotrelvir-ritonavir reduces time to recovery (-35.8 median hours; high CoE) and probably increases adverse events (28.9% vs. 21.6%; moderate CoE). There was no difference in recovery between molnupiravir and favipiravir (high CoE) and nirmatrelvir-ritonavir and molnupiravir (low CoE).
LIMITATION: Evidence for many outcomes is limited.
CONCLUSION: Three COVID-19 antivirals improved or accelerated recovery, with varying adverse event profiles. Molnupiravir probably offers long-term benefits.
PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD420251029146; OSF: https://osf.io/ywp6u).
Commentaires cliniques (en anglais)
Infectious Disease
A useful summary of data from trials of outpatient treatments for COVID-19 as of September 2025.
Infectious Disease
A useful article that looks at oral treatment for outpatients with COVID. It is notable that it includes medications that are not currently available in the United States.
Public Health
Excellent evidence synthesis of a still important topic.
Voulez-vous savoir ce que lisent les professionnels? Inscrivez-vous pour accéder gratuitement à tous les contenus professionnels.
S'inscrireNos contenus
À propos
Le soutien au Portail est largement assuré par l’Initiative Labarge sur le vieillissement optimal. AGE-WELL est un partenaire contributeur. Aidez-nous à continuer à fournir un accès direct et facile à des informations fondées sur des données probantes sur des enjeux de santé et sociaux pour vous aider à rester en bonne santé, actif et engagé en vieillissant. Faites un don dès aujourd'hui.
